Testing ODC-IL2 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called ODC-IL2 for people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to help your immune system fight cancer. The study starts with small doses to find the best dose, then expands to see how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced or metastatic solid tumor that has not responded to or cannot be treated with standard therapies.
- Your tumor can be measured on a scan (like a CT or MRI).
- You are able to take care of yourself and perform daily activities (ECOG score 0 or 1).
- You have adequate liver and kidney function, as shown by blood tests.
- You have not had a previous organ transplant or an autoimmune disease requiring treatment in the last 2 years.
- You are not pregnant or breastfeeding, and you agree to use effective contraception during and for 4 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called DT-7012, given alone or with another immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if DT-7012 can shrink tumors or slow their growth.
This study tests a new treatment that uses your own immune cells, called TIL, to fight advanced solid tumors. It may be given alone or with another drug that helps the immune system attack cancer. The goal is to see if this treatment is safe and effective for people who have already tried other treatments.
This trial is testing a new drug called OTP-01 that targets two proteins (PD-1 and VEGFR2) to help your immune system fight cancer and stop tumors from growing. It is for people with advanced solid tumors that have not responded to or cannot have standard treatments.
This trial tests a type of immune cell treatment called TIL (tumor-infiltrating lymphocytes) in people with advanced solid cancers. It may help your immune system better recognize and attack tumors, especially if standard treatments have not worked.
This trial tests a new drug, D3L-002, for people with advanced solid tumors that have stopped responding to at least one prior treatment or have no standard options. The goal is to see if it can help shrink or control the cancer.
This trial tests an experimental drug called OBI-902 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if OBI-902 can help shrink or control the cancer.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.